Daniel P. Petrylak, MD

GU Oncology Now

<p>Daniel P. Petrylak, MD, a Professor of Medicine and Urology at the Yale School of Medicine, overviews the TROPHY-U-01 study for platinum-ineligible patients with metastatic urothelial carcinoma who have progressed on checkpoint inhibitor therapy.</p>


TROPHY-U-01: Sacituzumab Govitecan for Platinum-ineligible Metastatic UC

American Society of Clinical Oncology Genitourinary Cancers Symposium 2023

ASCO GU Symposium 2023

Daniel P. Petrylak, MD, overviews the TROPHY-U-01 study for platinum-ineligible patients with metastatic UC who have progressed on checkpoint inhibitor therapy.

Sacituzumab Govitecan for Platinum-ineligible mUC

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe